| Sonstiges: |
- Nachgewiesen in: USPTO Patent Applications
- Sprachen: English
- Document Number: 20120108522
- Publication Date: May 3, 2012
- Appl. No: 13/343299
- Application Filed: January 04, 2012
- Claim: 1. A method of treating a hormone resistant cancer in a subject having or suspected of having the hormone resistant cancer, comprising the step of administering to the subject an effective amount of the following: a histone deacetylase inhibitor selected from the group consisting of PXD-101, LBH589, FK228, MGCD-0103, R306465, PCI-24781, SB-939, ITF-2357, SAHA, CI-994, and MS-275; and an aromatase inhibitor.
- Claim: 2. The method of claim 1, wherein the hormone resistant cancer is breast cancer.
- Claim: 3. The method of claim 1, wherein the aromatase inhibitor is selected from the group consisting of anastrozole, exemestane, letrozole, formestane, and testolactone.
- Claim: 4. The method of claim 2, wherein the breast cancer is estrogen receptor negative.
- Claim: 5. The method of claim 2, wherein the breast cancer is estrogen receptor positive.
- Claim: 6. The method of claim 1, wherein the histone deacetylase inhibitor and the aromatase inhibitor are administered simultaneously.
- Claim: 7. The method of claim 1, wherein the histone deacetylase inhibitor is administered prior to the administration of the aromatase inhibitor.
- Claim: 8. The method of claim 1, wherein the histone deacetylase inhibitor is administered subsequent to the administration of one or more dose of the aromatase inhibitor.
- Claim: 9. The method of claim 1, wherein the histone deacetylase inhibitor and the aromatase inhibitor act synergistically.
- Claim: 10. The method of claim 1, wherein the histone deacetylase inhibitor is MS-275.
- Claim: 11. The method of claim 1, wherein the hormone resistance is acquired resistance.
- Claim: 12. A method of treating a hormone resistant cancer in a subject having or suspected of having the hormone resistant cancer, comprising the step of administering to the subject an effective amount of the following: a histone deacetylase inhibitor; and an aromatase inhibitor selected from the group consisting of anastrozole, exemestane, letrozole, formestane, and testolactone.
- Claim: 13. The method of claim 12, wherein the hormone resistant cancer is a hormone resistant breast cancer.
- Claim: 14. The method of claim 13, wherein the breast cancer is estrogen receptor negative.
- Claim: 15. The method of claim 13, wherein the breast cancer is estrogen receptor positive.
- Claim: 16. The method of claim 12, wherein the histone deacetylase inhibitor is SAHA, CI-994, PXD-101, LBH589, FK228, MGCD-0103, R306465, PCI-24781, SB-939, ITF-2357, and MS-275.
- Claim: 17. The method of claim 12, wherein the histone deacetylase inhibitor is MS-275.
- Claim: 18. The method of claim 12, wherein the hormone resistance is acquired resistance.
- Claim: 19. A method of treating a hormone resistant breast cancer in a subject having or suspected of having the hormone resistant breast cancer, comprising the step of administering to the subject an effective amount of the following: a histone deacetylase inhibitor selected from the group consisting of SAHA, CI-994, PXD-101, LBH589, FK228, MGCD-0103, R306465, PCI-24781, SB-939, ITF-2357, and MS-275; and an aromatase inhibitor selected from the group consisting of anastrozole, exemestane, letrozole, formestane, testolactone, and a combination thereof.
- Claim: 20. The method of claim 19, wherein the breast cancer is ER−, PR+.
- Claim: 21. The method of claim 19, wherein the breast cancer is ER−, PR− and Her2+.
- Claim: 22. The method of claim 19, wherein the breast cancer is ER−, PR− and Her2−.
- Claim: 23. The method of claim 19, wherein the histone deacetylase inhibitor is MS-275.
- Claim: 24. The method of claim 19, wherein the hormone resistance is acquired resistance.
- Claim: 25. A method of inhibiting growth of a cell comprising contacting the cell with an aromatase inhibitor and a histone deacetylase inhibitor, each in an effective amount to inhibit growth of said cell, wherein the histone deacetylase inhibitor is selected from the group consisting of PXD-101, LBH589, FK228, MGCD-0103, R306465, PCI-24781, SB-939, ITF-2357, SAHA and CI-994 and MS-275.
- Claim: 26. The method of claim 25, wherein the aromatase inhibitor is selected from the group consisting of anastrozole, exemestane, letrozole, formestane, testolactone, and a combination thereof.
- Claim: 27. The method of claim 25, wherein the histone deacetylase inhibitor is MS-275.
- Claim: 28. The method of claim 25, wherein the hormone resistance is acquired resistance.
- Claim: 29. A method of inhibiting growth of a cell comprising contacting the cell with an aromatase inhibitor and a histone deacetylase inhibitor, each in an effective amount to inhibit growth of said cell, wherein the aromatase inhibitor is selected from the group consisting of anastrozole, exemestane, letrozole, formestane, testolactone, and a combination thereof.
- Claim: 30. The method of claim 29, wherein the cell is a refractory cancer cell and the hormone resistance is acquired resistance.
- Claim: 31. The methods of claim 29, wherein the histone deacetylase inhibitor increases the expression of an estrogen receptor on the cell.
- Claim: 32. The method of claim 29, wherein the histone deacetylase inhibitor increases the expression or activity of aromatase in the cell.
- Claim: 33. The method of claim 29, wherein the contacting occurs in vivo.
- Claim: 34. The method of claim 29, wherein the histone deacetylase inhibitor is MS-275.
- Claim: 35. The method of claim 29, wherein the hormone resistance is acquired resistance.
- Claim: 36. A method of treating a hormone resistant cancer in a subject having or suspected of having the hormone resistant cancer, comprising the step of administering to the subject an effective amount of the following: a histone deacetylase inhibitor; and an anti-androgen, wherein the anti-androgen is not a 17alpha-hydroxylase-C17,20-lyase inhibitor or a 5-reductase inhibitor.
- Claim: 37. The method of claim 36, wherein the hormone resistant cancer is prostate cancer.
- Claim: 38. The method of claim 36, wherein the histone deacetylase inhibitor is a selective histone deacetylase inhibitor.
- Claim: 39. The method of claim 36, wherein the histone deacetylase inhibitor is selected from the group consisting of SAHA, CI-994, PXD-101, LBH589, FK228, MGCD-0103, R306465, PCI-24781, SB-939, ITF-2357, and MS-275.
- Claim: 40. The method of claim 36, wherein the anti-androgen is selected from the group consisting of spironolactone (Aldactone, Spiritone; Novo-Spiroton, Spiractin, Verospiron or Berlactone), cyproterone acetate (Androcur, Climen, Diane 35, Ginette 35), flutamide (Eulexin), nilutamide (Anandron, Nilandron), bicalutamide (Casodex) and a combination thereof.
- Claim: 41. The method of claim 36, wherein the histone deacetylase inhibitor and the anti-androgen are administered simultaneously.
- Claim: 42. The method of claim 36, wherein the histone deacetylase inhibitor is administered prior to the administration of the anti-androgen.
- Claim: 43. The method of claim 36, wherein the histone deacetylase inhibitor and the anti-androgen act synergistically.
- Claim: 44. The method of claim 36, wherein the hormone resistance is acquired resistance.
- Current U.S. Class: 514/194
- Current International Class: 61; 61; 61; 61; 61; 61; 61; 61
|
